Type 2 Diabetes

Jennifer Green, MD, explains how delays in the adoption of new guideline recommendations are holding back optimal management of type 2 diabetes in the US.

Erica P. Gunderson, PhD, MS, MPH, offers perspective on the current state of gestational diabetes management as well as avenues for improving current diagnostic and management standards.

HCPLive Crisis Point takes an in-depth look at the obesity crisis, beginning with the process of medical diagnosis and who is impacted the most by the disease.

Vivian Fonseca, MD, reflects on the 100-year anniversary of the discovery of insulin and how the role of insulin has evolved since Sir Frederick Banting's historic discovery.

After presenting at TMIOA's 5th Heart in Diabetes meeting, Silvio Inzucchi, MD, reviews current knowledge related to the effects of diabetes medications on stroke risk.

The TMIOA Medical Director and Principal Investigator discusses the idea behind hosting a mixed in-person and virtual conference for this year's Heart in Diabetes.

Silvio Inzucchi, MD, discusses his presentation on the role of diabetes medications, including SGLT2 inhibitors and GLP-1 RAs, in stroke prevention from TMIOA's 5th Heart in Diabetes conference.

A discussion on the winning qualities of the CARDIA study, and why it's also hard to replicate.

A 12-week trial assessing the effects of a low calorie, low carbohydrate diet facilitated by community pharmacists suggests this approach could contribute to the remission of type 2 diabetes in adult patients.

Dr. Javed Butler referenced several promising ongoing trials of diabetes-related medications and their effects on heart disease but added that unclear guidelines kept them from being properly acknowledged.

Though select diabetes guidelines suggest the use of continuous glucose monitoring on patients with diabetic patients on intensive therapy, the potential benefits on type 2 patients without insulin and pre-diabetes patients has yet to be fully explored.

Though limited data exist, Dr. Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

The Tulane Chief of Endocrinology recalls Dr. Frederick Banting's historic discovery in 1921, and how it still impacts diabetes care today.

Women with gestational diabetes face a twice greater risk of developing cardiovascular disease. Investigators are still seeking understanding of the association.

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.

While drivers of gestational diabetes are not fully evidenced, data shows how it's linked to great likelihood of type 2 diabetes and cardiovascular events.

Despite having lower burden of several cardiovasculard disease risk factors, cardiovascular mortality is higher in African Americans, which Dr. Dagogo-Jack attributes to disparities in patient care.

Dr. Peter Grant admits that the phenotypes surrounding certain cardiovascular diseases are complex, but notes treatments can be recommended based on individual patients’ complications.

Though the trial observing dapagliflozin for severe COVID-19 did not achieve statistical significance, investigators believe it showed the agent's benefit in acute illness.

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

A 3-year study with more than 500 patients, results suggest none of the study participants had a BCVA worse than 0.3 (log MAR 0.48) due to diabetic retinopathy.